Skip to Content


Paperwork Reduction Act; Notice of Intent To Collect; Comment Request

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble


Office of National Drug Control Policy (ONDCP).


ONDCP provides opportunity for public comment concerning the collection of information to identify the Start Printed Page 72771Federal, State, and local resources assigned to drug control programs in our nation's largest cities.


This action proposes the collection of drug control information from federal, state, and local governments.

End Preamble Start Supplemental Information


I. Background

ONDCP previously collected information to establish a baseline of federal, state, and local drug control funding levels in the nation's largest metropolitan areas. The collection of this data will help ONDCP measure spending level changes, coordinate services, and develop National Drug Control Strategies.

The project identifies in each affected city significant movements in key drug use measures, and encourages city administrators to use proven programs that increase efficiencies and effectiveness; promote coordination and collaboration; develop commitments; and, gather accurate performance measurement data.

Type of Collection: Reinstatement with change of an approved data collection that expired.

Title of Information Collection: Survey of drug treatment, drug use prevention, and law enforcement resources available to cities.

Frequency: Annually by fiscal year.

Affected Public: Instrumentalities of State, local, and tribal governments.

Estimated Burden: Minimal since providers maintain the data for other purposes.

II. Special Issues for Comment

ONDCP especially invites comments on: (a) Whether the proposed collection is necessary for the proper performance of ONDCP functions, including whether the information has practical utility; (b) ways to enhance information quality, utility, and clarity; and (c) ways to ease the burden on respondents, including the use of automated collection techniques or other forms of information technology.


Address all comments in writing within 60 days to Michael Reles. Facsimile and e-mail are the more reliable means of communication. Mr. Reles's facsimile number is (202) 395-5176, and his e-mail address is The Web site for the ONDCP is Mailing address is Executive Office of the President, Office of National Drug Control Policy, Washington, DC 20503. For further information, contact Mr. Reles at (202) 395-6608.

Start Signature

Signed at Washington DC on December 18, 2007.

Daniel R. Petersen,

Assistant General Counsel.

End Signature End Supplemental Information

[FR Doc. E7-24870 Filed 12-20-07; 8:45 am]